TNFRSF18 and type 2 diabetes mellitus: Potent activators of adipose ILC2s such as tumor necrosis factor (TNF) superfamily receptors like GITR (20)and TNFRSF25 (DR3) (28, 134, 135) may be possible therapeutic targets for human T2DM treatment as their agonists promote adipose homeostasis and glucose tolerance in mouse models (20, 28).